Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

161. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study (Abstract)

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial. This regional trial evaluated the efficacy and safety of trifluridine/tipiracil in Asian patients with mCRC with or without exposure to biologic (...) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase III trial was conducted at 30 sites in China, the Republic of Korea, and Thailand. Patients ≥ 18 years old with histologically or cytologically confirmed adenocarcinoma of the colon or rectum and known KRAS status who were refractory or intolerant to two or more prior chemotherapy regimens were enrolled. Eligible patients were randomly assigned (2:1 ratio; minimization method) to receive trifluridine/tipiracil

2018 EvidenceUpdates

162. Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations Full Text available with Trip Pro

Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations 29552663 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations. 12 10.21037/tgh.2018.02.01 Eckardt Alexander J AJ Department of Gastroenterology, DKD Helios Klinik Wiesbaden (...) -2018.02.01 PMC5847923 Ann Surg. 2000 Jan;231(1):51-8 10636102 J Clin Oncol. 2012 Jul 1;30(19):2401-7 22614970 N Engl J Med. 2002 Aug 15;347(7):472-80 12181401 Cancer Res Treat. 2017 Apr;49(2):350-357 27456941 Med Oncol. 2013 Jun;30(2):522 23456621 Lancet. 2013 Jan 26;381(9863):295-302 23177515 Eur J Cancer. 2014 Mar;50(5):981-6 24388774 Science. 1998 Jan 23;279(5350):577-80 9438854 World J Gastroenterol. 2017 Jul 21;23 (27):4856-4866 28785140 Ann Oncol. 2016 Sep;27(9):1794-9 27371698 Int J Clin Oncol

2018 Translational gastroenterology and hepatology

163. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma Full Text available with Trip Pro

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma The aim of this study was to evaluate the optimal sequence of targeted therapies (epidermal growth factor receptor inhibitors (EGFRi) and vascular endothelial growth factor inhibitors (VEGFi)), combined with chemotherapy, in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). Exploratory analyses of overall (...) survival (OS) for patients treated with either first-line panitumumab (EGFRi) and second-line VEGFi therapy, or first-line bevacizumab (VEGFi) and second-line EGFRi, were conducted.Patients from PEAK (NCT00819780), PRIME (NCT00364013) and Study 181 (NCT00339183), with RAS WT or RAS WT/BRAF WT tumours, were included in the analyses. OS data were pooled for patients receiving first-line panitumumab (PEAK and PRIME) or first-line bevacizumab (PEAK and 181), followed by second-line VEGFi or EGFRi

2018 ESMO open

164. Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer Full Text available with Trip Pro

Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer Inflammation promotes the development of malignancy, while a variety of systemic markers of inflammation predict for worse cancer outcomes including recurrence and survival. Here, we evaluate the prognostic impact of cytokine concentrations, full blood count (FBC) differential ratios, cognitive function and fatigue on survival in patients with localised colorectal (...) of the cytokines (interleukin (IL-6), IL-1 and tumour necrosis factor) or differential ratios of blood components, fatigue or cognitive function was statistically related to DFS or OS. Patient educational status (P=0.018), stage of disease (P=0.032), alanine transaminase (P=0.003), lactate dehydrogenase (P=0.008) and carcinoembryonic antigen (P=0.002) were significant as prognostic covariates of OS in univariable analyses, with similar results for DFS.None of the a priori selected markers of inflammation

2018 ESMO open

165. Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for Colorectal Cancer: Randomized Controlled Trial Full Text available with Trip Pro

Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for Colorectal Cancer: Randomized Controlled Trial People seek information on the Web for managing their colorectal cancer (CRC) risk but retrieve much personally irrelevant material. Targeting information pertinent to this cohort via a frequently asked question (FAQ) format could improve outcomes.We identified and prioritized colorectal cancer information for men and women aged 35 to 74 years (study 1) and built (...) a website containing FAQs ordered by age and gender. In study 2, we conducted a randomized controlled trial (RCT) to test whether targeted FAQs were more influential on intention to act on CRC risk than the same information accessed via a generic topic list. Secondary analyses compared preference for information delivery, usability, relevance, and likelihood of recommendation of FAQ and LIST websites.Study 1 determined the colorectal cancer information needs of Australians (N=600) by sex and age group

2018 JMIR cancer Controlled trial quality: uncertain

166. SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment Full Text available with Trip Pro

SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment 29552661 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment. 10 10.21037/tgh.2018.01.09 Trautmann Marcel M Gerhard-Domagk-Institute of Pathology, University Hospital Münster (...) Cancer. 2014 Aug;21(4):567-77 24859990 J Clin Oncol. 2008 Nov 20;26(33):5360-7 18955451 J Gastrointest Surg. 2012 Sep;16(9):1645-7 22752549 Science. 1998 Jan 23;279(5350):577-80 9438854 Clin Cancer Res. 2008 Jul 15;14(14):4550-5 18628470 Ann Oncol. 2010 May;21 Suppl 5:v98-102 20555113 Mod Pathol. 2013 Jul;26(7):1004-12 23599150 Am J Gastroenterol. 2005 Jan;100(1):162-8 15654796 J Clin Oncol. 2010 Mar 1;28(7):1247-53 20124181 Cancer. 2005 Feb 15;103(4):821-9 15648083 Expert Rev Anticancer Ther. 2015

2018 Translational gastroenterology and hepatology

167. Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines Full Text available with Trip Pro

Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines There are some disparities between the clinical practice and profiles of cancer in Asia and those in Europe & North America. In Asia, surgical oncologists still have a major role in the multidisciplinary therapy of gastrointestinal stromal tumor (GIST), whereas medical oncologists hold this status in the West. Although the incidence of clinical GIST is considered similar (...) between the two areas, small gastric GISTs are more frequently treated by surgery in East Asia compared with Europe & North America. The diagnosis and treatment of small submucosal tumors (SMTs), including GIST, is important in Asian clinical practice guidelines for GIST. Most items of Asian and Western GIST guidelines are very similar. There are slight differences between the two guidelines in the degree of recommendation, which may come from disparities of clinical practice and available medicines

2018 Translational gastroenterology and hepatology

168. Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells Full Text available with Trip Pro

Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells Colorectal cancer (CRC) is the third most leading cause of morbidity and mortality throughout the world. 5-fluorouracil (5-FU), which is often administrated to disrupt carcinogenesis, was found to elevate blood glucose level among CRC patients. Thus, this study was conducted to evaluate the influence of rosiglitazone on antiproliferative effect of 5-FU using cellular model. Two (...) human colonic carcinoma cell lines (HCT 116 and HT 29) were cultured in the presence of 5-FU, rosiglitazone or in combination under normal and high glucose concentration. The drug cytotoxicity was evaluated using the MTT assay whereas the assessment of cell cycle was carried out using the flow cytometry technique. Combination index (CI) method was used to determine the drug interaction between rosiglitazone and 5-FU. High glucose diminished the cytotoxic effect of 5-FU but at a high drug dosage

2018 EXCLI journal

169. Bevacizumab (Mvasi) - Cancer, colon, breast, lung, kidney, ovary, cervix

(EMA) for MVASI, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant applied for the following indications: MVASI in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. MVASI in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information (...) of cytotoxic chemotherapy (Goel et al, 2011). The Applicant claimed the same therapeutic indications and posology for the proposed biosimilar Mvasi as granted for Avastin in the European Union (EU): • MVASI in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. • MVASI in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. Assessment report EMA

2018 European Medicines Agency - EPARs

170. Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy

Publication date: 18/10/2017 Abstract Authors’ conclusions: exposure to infliximab is not associated with an increased risk of malignancy or hemophagocytic syndrome in children with inflammatory bowel disease. Exposure to thiopurines is an important antecedent for the development of these complications. Reviewers’ commentary: the use of infliximab and other biological therapies does not seem to increase the risk of onset of tumors in the medium term, although it would be advisable to prolong the follow-up (...) Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password

2018 Evidencias en Pediatría

171. Management of rectal gastrointestinal stromal tumor Full Text available with Trip Pro

Management of rectal gastrointestinal stromal tumor Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor (...) receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep

2018 Translational gastroenterology and hepatology

172. Lonsurf for Metastatic Colorectal Cancer – Details

Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details Project Number pCODR 10122 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic Colorectal Cancer Funding Request For the treatment of adult patients with metastatic (...) colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada, Inc. Submitter Taiho Pharma Canada, Inc. Submission Date November 6, 2017 Submission Deemed Complete November 13, 2017 Submission Type New Drug

2018 CADTH - Pan Canadian Oncology Drug Review

173. Microsatellite instability in colorectal cancer Full Text available with Trip Pro

as the presence of alternate sized repetitive DNA sequences which are not present in the corresponding germ line DNA. The presence of MSI is found in sporadic colon, gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectal cancers display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications. As well, detecting MSI is used diagnostically for tumor detection and classification. For these reasons, microsatellite instability analysis (...) Microsatellite instability in colorectal cancer Colorectal cancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers if it is detected in the early stages. Molecular changes that occur in colorectal cancer may be categorized into three main groups: 1) Chromosomal Instability (CIN), 2) Microsatellite Instability (MSI), and 3) CpG Island

2018 EXCLI journal

174. Gastrointestinal stromal tumor of the esophagus: current issues of diagnosis, surgery and drug therapy Full Text available with Trip Pro

Gastrointestinal stromal tumor of the esophagus: current issues of diagnosis, surgery and drug therapy Gastrointestinal stromal tumors (GISTs) often arise in the stomach and small intestine, while esophageal GISTs are rare. Due to their rarity, clinicopathological data on esophageal GISTs are extremely limited, and this results in a lack of clear recommendations concerning optimal surgical management for esophageal GISTs. It is difficult to distinguish esophageal GIST from leiomyoma, the most (...) frequent esophageal mesenchymal tumor, prior to resection, because the two types of tumors appear similar on computed tomography (CT), endoscopic ultrasound (EUS), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Fine-needle aspiration biopsy (FNAB) under EUS enables definitive diagnosis, but it is often avoided because scarring could make enucleation more difficult and increase the risk of tumor dissemination by capsule destruction. Esophageal segmental and wedge resections

2018 Translational gastroenterology and hepatology

175. Vectibix for Left Sided Metastatic Colorectal Cancer — Details

Vectibix for Left Sided Metastatic Colorectal Cancer — Details Vectibix for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Vectibix for Left Sided Metastatic Colorectal Cancer – Details Vectibix for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10118 Brand Name Vectibix Generic Name Panitumumab Strength 20 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request In combination (...) with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 31, 2015 Manufacturer Amgen Canada Inc. Submitter Amgen Canada Inc. Submission Date September 8, 2017 Submission Deemed Complete September 15, 2017 Submission Type New Indication Prioritization Requested Not Requested Stakeholder Input Deadline ‡ September 22, 2017 Check-point meeting October 30, 2017 pERC

2018 CADTH - Pan Canadian Oncology Drug Review

176. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date

2018 CADTH - Pan Canadian Oncology Drug Review

177. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al. Full Text available with Trip Pro

Colonic Neoplasms Colorectal Neoplasms Humans 2016 1 27 6 0 2016 1 27 6 0 2018 1 19 6 0 ppublish 26811349 mdw039 10.1093/annonc/mdw039 (...) Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al. 26811349 2018 01 18 2018 12 02 1569-8041 27 5 2016 05 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al. 957-8

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

178. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. Full Text available with Trip Pro

di Ricerche Farmacologiche Mario Negri, Milan roldano.fossati@marionegri.it. eng Letter Comment 2016 02 23 England Ann Oncol 9007735 0923-7534 0 Carcinoembryonic Antigen IM Ann Oncol. 2016 Feb;27(2):274-80 26578734 Ann Oncol. 2016 May;27(5):957-8 26811349 Carcinoembryonic Antigen Colonic Neoplasms Colorectal Neoplasms Humans 2016 2 26 6 0 2016 2 26 6 0 2018 1 19 6 0 ppublish 26912556 mdw076 10.1093/annonc/mdw076 (...) Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. 26912556 2018 01 18 2018 12 02 1569-8041 27 6 2016 06 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. 1171

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

179. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Full Text available with Trip Pro

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Constitutive activation of HER2-dependent intracellular signalling by HER2 gene amplification or by HER2 mutations has been demonstrated as a mechanism of primary and secondary cancer resistance to cetuximab or panitumumab in preclinical and clinical models of metastatic colorectal cancer (mCRC). Both HER2 Amplification for Colorectal (...) Cancer Enhanced Stratification (HERACLES) cohort A and My Pathway clinical trials provided clinical evidence that anti-HER2 therapies could be active in these patients.HER2 gene amplification and HER2 protein overexpression analysis were performed in tumour tissue by fluorescence in situ hybridisation and immunohistochemistry. HER2 positivity was defined according to HERACLES CRC-specific HER2 scoring criteria. DNA analysis for multiple assessment of gene mutations or amplifications was carried out

2018 ESMO open

180. Neoadjuvant therapy for gastrointestinal stromal tumor Full Text available with Trip Pro

Neoadjuvant therapy for gastrointestinal stromal tumor Molecular-targeting therapy using tyrosine kinase inhibitor imatinib mesylate is effective for metastasis/recurrent gastrointestinal stromal tumors (GISTs). Likewise, imatinib would be effective in the neoadjuvant therapy for high-risk GIST. Neoadjuvant therapy may have the potential to increase the complete resection rate and to avoid the surgical rupture by decreasing the tumor size. Thereby, it is expected that improvement of recurrence (...) rate and survival rate can be obtained by neoadjuvant therapy. Neoadjuvant therapy is also expected to be favored from the viewpoint of organ/function preservation by tumor shrinkage. The existing results of clinical trials established the feasibility of neoadjuvant imatinib therapy. However, proof of the survival effectiveness of neoadjuvant imatinib therapy has not been sufficiently demonstrated. The aim of this article is to introduce previous evidence and strategies regarding neoadjuvant

2018 Translational gastroenterology and hepatology